The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”

The final workout of the 2019 Open featured a descending ladder of thrusters and chest-to-bar pull-ups, totaling 105 reps of each movement, with a 20-minute time cap. Last year, 18.5 presented athletes with an ascending ladder of the same two movements, so it’s no surprise that nearly the same percentage of Open participants decided to tackle the final Open workout as prescribed in 2018 and 2019. Read on to see how the community fared with this year's rep scheme.
×